RNA Pioneer Dr. Phillip Zamore Joins TransCode Therapeutics' Scientific Advisory Board

TransCode Therapeutics has strategically strengthened its scientific expertise by appointing Dr. Phillip D. Zamore to its Scientific Advisory Board. Dr. Zamore, a distinguished researcher in RNA biology and gene silencing mechanisms, brings extensive credentials and pioneering experience to the clinical-stage oncology company.

As Chair of the RNA Therapeutics Institute at UMass Chan Medical School and a co-founder of Alnylam Pharmaceuticals, Dr. Zamore represents a significant addition to TransCode's scientific leadership. His national recognition, including election to the National Academy of Sciences, underscores the potential impact of his involvement with the company.

TransCode is currently developing innovative RNA therapeutics focused on treating metastatic cancer, with its lead candidate TTX-MC138 targeting tumors that overexpress microRNA-10b. Dr. Zamore's expertise in RNA interference could prove crucial in advancing the company's proprietary TTX nanoparticle platform and expanding its therapeutic approaches.

The appointment signals TransCode's commitment to cutting-edge cancer research and its ambition to develop novel genetic therapies. By bringing a world-renowned RNA biology expert onto its Scientific Advisory Board, the company demonstrates its dedication to pushing the boundaries of cancer treatment through advanced RNA therapeutic strategies.